Gynecology and Obstetrics

Gynecology

The Risk. Thromboembolic complications after gynecologic surgery occur with approximately the same frequency as for general surgery (Table 5.1). Pulmonary embolism (PE) is a leading cause of death following gynecologic cancer surgery and accounts for approximately 20% of the perioperative hysterectomy deaths. Patients undergoing major gynecologic surgery (eg, over 30 minutes duration) aged 40 years or above have a significant risk of postoperative venous thromboembolism (VTE). The risk is increased by age, obesity, malignancy, history of VTE, immobility, and hereditary or acquired thrombophilia. This risk is also affected by the nature and duration of the operation, type of anesthesia, dehydration, sepsis, varicose veins, and hormone therapy. Known clinical risk factors allow for classification of patients into high, moderate, and low risk of developing VTE (Table 5.2).

The incidence of symptomatic VTE appears to be minimal for benign laparoscopic gynecologic surgery and as high as 16% in surgery for ovarian cancer. As indicated above, a common additional risk factor for VTE is estrogen contained in combined oral contraceptives (COCs), which had been used by 18% of women in a UK study. The COCs increase the risk of VTE. However, the absolute risk is small and represents an increase from 5 to 15 to 30 per 1 00 000 women years. The latter is lower than the risk of pregnancy, which is estimated at 100 cases per 1 00 000 maternities. The risk of postoperative VTE showed an increase from 0.5% to 1% for pill users versus nonusers in early studies. The absolute excess risk in COC users has to be balanced against the risk of stopping the pill 4 to 6 weeks before surgery which includes unwanted pregnancy, the effects of surgery and anesthesia on a pregnancy, and the risks of subsequent termination. Each case should be assessed in relation to additional risk factors. Before major surgery, COCs should be discontinued for at least 4 weeks and alternative contraception should be advised. If it is elected not to discontinue COCs, then the patient should receive prophylaxis as if for at least a moderate-risk patient. Other estrogen-containing preparations should be considered to carry the same risk as COCs at least until studies become available. In emergency surgery or when COCs have not been discontinued, VTE prophylaxis should be given at least as moderate-risk category. The COCs do not need to be discontinued before minor surgery without immobilization. Progestogen-only oral contraceptives need not be discontinued even when immobilization is expected. For other contraceptive preparations, consult the manufacturers’ data sheets.

Hormone replacement therapy (HRT) should be included as a risk factor for VTE when assessing patients for elective or emergency surgery. The HRT does not need to be stopped routinely prior to surgery provided that appropriate thromboprophylaxis is used such as low-molecular-weight heparin (LMWH). An individual assessment is required in each woman to balance the risks of postoperative VTE against the changes in the quality of life which may result from cessation of the therapy. Transdermal HRT has less effect on blood coagulation and appears to have a substantially lower VTE risk than oral HRT.

In assisted reproduction, ovarian stimulation is used which results in a hyperestrogen state and activation of coagulation. The risk of venous thrombosis is increased and even upper extremity deep vein thrombosis (DVT) extending to subclavian and internal jugular veins can occur. In women with ovarian hyperstimulation syndrome, thromboprophylaxis with pregnancy dosage of LMWH is advised.

Prophylactic Methods and Recommendations

General Considerations

Low-risk patients. A randomized controlled trial (RCT) involving 196 patients demonstrated a lower DVT rate with the use of graduated elastic compression (GEC) versus no GEC (0% vs 4%; P < .05) in women undergoing major gynecological surgery. On the basis the risk–benefit ratio in this study and extrapolation of data from moderate-risk patients and general surgery, thromboprophylaxis with GEC stockings should be used in addition to early ambulation and adequate hydration.

Moderate-risk patients. Two RCTs involving 207 patients having surgery predominantly for benign gynecologic disease showed that low-dose unfractionated heparin (LDUH 5000 IU, 12 hours) reduced DVT. The LDUH reduced asymptomatic DVT from 25% to 4.8% (risk ratio [RR] 0.19; 95% confidence interval [CI] 0.07-0.48). The LMWH (initiated and dosed according to the labeling) is equally effective for preventing DVT. There are no RCT in patients having laparoscopic gynecologic surgery. Patients undergoing complex laparoscopic surgery appear to be at similar VTE risk to those having open procedures.

High-risk patients. In patients having gynecologic surgery for malignancy, LDUH administered 12-hourly was not effective but LDUH administered 8-hourly was effective. The latter reduced asymptomatic DVT from 18.4% in the control group to 8.7% in the LDUH group (RR 0.47; 95% CI 0.22-0.98). Subsequent RCTs in patients having gynecologic oncology surgery have shown no difference in the efficacy between LMWH and LDUH given 3 times daily for thromboprophylaxis against DVT or PE and no difference in the risk of bleeding. The risk of wound hematomas appears to be reduced by avoiding subcutaneous injection near the wound. The LMWH has the advantage of once daily injection and is less likely to cause heparin-induced thrombocytopenia (HIT). Extrapolating from general surgery, fondaparinux is an alternative to LMWH. Intermittent pneumatic compression (IPC) has been shown to be as effective as LDUH or LMWH for preventing DVT when used continuously for 5 days without any bleeding complications. Thus, in patients with a high risk of bleeding, IPC can be used as an alternative to heparin prophylaxis until the patient is ambulatory.
In a RCT involving 208 patients undergoing gynecologic surgery for malignancy, LDUH and IPC provided a similar reduction in the incidence of postoperative DVT, but LDUH was associated with a higher frequency of bleeding complications.

In a RCT involving 332 patients undergoing surgery for abdominal and pelvic malignancy of which 8% were gynecologic operations, 4 weeks of prophylaxis with LMWH reduced venographic DVT from 12.0% in the 1-week prophylaxis group to 4.8% in the 4-week prophylaxis group (RR 0.40; 95% CI 0.18-0.88).

**Recommendations.** Low-risk patients should receive thromboprophylaxis with GEC (level of evidence: moderate) in addition to early ambulation and adequate hydration.

For moderate-risk patients LDUH (5000 IU, 12 hours), LMWH (initiated and dosed according to labeling), or IPC is recommended (level of evidence: high). The LMWH is the preferred method because it has the advantage of once daily injection and is less likely to cause HIT. The IPC is the method of choice in patients with a high risk of bleeding (level of evidence: high).

In high-risk patients, LMWH (initiated and dosed according to labeling; level of evidence: high), fondaparinux (level of evidence: low), LDUH (5000 IU 8 hours; level of evidence: high), or IPC (throughout hospital stay; level of evidence: moderate) is recommended. The LMWH or LDUH combined with IPC or GEC stockings provide optimal prophylaxis (level of evidence: moderate). Consideration should be given to continuing thromboprophylaxis after hospital discharge with LMWH for up to 28 days especially in patients with cancer (level of evidence: low) extrapolated from the general surgery.

Until further evidence is available, patients undergoing complex laparoscopic surgery should be provided with prophylaxis in accordance with risk category similar to patients undergoing open procedures (level of evidence: low).

**Obstetrics**

**The Risk.** Pregnancy is a risk factor for VTE with nearly a 5-fold increase compared to the risk of nonpregnant women. The puerperium is the time of greatest risk, with a 20-fold increase. The PE was the leading direct cause of maternal deaths in the United Kingdom until 2005. The most recent report “Saving Mothers’ Lives” has shown for the first time...
a sharp fall in the deaths from VTE which is attributed to better recognition of high-risk women and more widespread use of thromboprophylaxis.\textsuperscript{36,37} Recent publications have better quantified the magnitude of risk associated with key risk factors in pregnancy.\textsuperscript{38,39} Risk factors for VTE in pregnancy are foremost a history of thrombosis,\textsuperscript{40,41} thrombophilia, immobility, obesity, and postpartum hemorrhage.\textsuperscript{38} Other risk factors include age above 35 years, cesarean section, especially as an emergency in labor, coexisting medical problems, and surgical procedures during pregnancy and the puerperium.\textsuperscript{39,42} There are significant interactions of risk factors when multiple risk factors are present. Risk assessment for VTE is recommended for all women in early pregnancy and prior to cesarean section.\textsuperscript{36}

**Prophylactic Methods and Recommendations**

**General Considerations.** The Cochrane Review of VTE prophylaxis in pregnancy and the puerperium examined 8 trials involving 649 women. It was not possible to assess the effects of interventions because of the limited number of trials and the small sample sizes.\textsuperscript{43} Although large-scale randomized trials of currently used interventions are required for evidence-based recommendations, practice has evolved based on indirect evidence.

Table 5.3 summarizes management strategies for various clinical situations. In the absence of RCT, all recommendations are based on low levels of evidence.

Women at high risk of VTE including those with previous confirmed VTE should be offered prepregnancy counseling to agree to a management plan. The thrombotic risk exists from the beginning of pregnancy.\textsuperscript{38,44}

Women with previous VTE or a strong family history of VTE, particularly where familial VTE occurs at a young age (<50 years), should be screened for inherited and acquired thrombophilia before pregnancy (level of evidence: low). Ideally, all women should undergo assessment of risk factors for VTE in early pregnancy or before pregnancy. This assessment should be repeated if the woman is admitted to a hospital with complications such as hyperemesis or preeclampsia that requires bed rest (level of evidence: low).\textsuperscript{45,46} Systematic reviews and retrospective studies have concluded that prophylaxis with LMWH is now the method of choice in pregnancy compared to LDUH in view of efficacy and safety\textsuperscript{47,51} (level of evidence: low). The risks of HIT and osteoporosis during pregnancy are low with LMWH when compared to LDUH.\textsuperscript{52,53} The overall risk of recurrence of DVT during pregnancy has been reported as high as 10.9\% compared to 3.7\% outside pregnancy.\textsuperscript{54,55}

Women who have had a previous VTE in association with a temporary risk factor that is no longer present and no known thrombophilia or additional risk factors should be offered antepartum and/or postpartum thromboprophylaxis with LMWH (level of evidence: low). The GEC stockings during pregnancy should be considered in addition to postpartum prophylaxis (level of evidence: low). Women in whom a previous VTE was oestrogen related (pregnancy or the combined contraceptive pill) or additional risk factors such as obesity are present should be started with thromboprophylaxis with LMWH as early as possible in pregnancy and continued for 6 weeks following delivery (level of evidence: low).

Women with thrombophilias have an increased risk of VTE in pregnancy and the risk varies with the specific thrombophilia. Women with previous VTE and certain thrombophilias such as those homozygous for factor V Leiden (FVL) should be offered thromboprophylaxis with LMWH antenatally and throughout the 6 weeks postpartum (level of evidence: moderate).

Women who are on long-term anticoagulant thromboprophylaxis for VTE and women with antithrombin deficiency are at very high risk (30\%) during pregnancy. Those on vitamin K antagonists should be advised to switch to LMWH as soon as pregnancy is confirmed because of the risk of embryopathy from warfarin between the sixth and twelfth week of pregnancy. In both situations, LMWH dosage should be similar to that used for the treatment of VTE (level of evidence: moderate).

Table 5.4 shows the most recent Royal College of Obstetricians and Gynaecologists (RCOG 2009) guidelines for recommended LMWH dosage in pregnancy. Reports have shown that a once-daily dosage of tinzaparin provides adequate 24-hour cover.\textsuperscript{56,57} A large retrospective audit of tinzaparin use in 1267 pregnancies in 1120 women showed the efficacy and safety compared well with its use in the nonpregnant population.\textsuperscript{58}

Women with a previous VTE and a thrombophilia such as protein C deficiency, FVL, prothrombin 20210A, or protein S deficiency who are at moderately increased risk of VTE should receive LMWH (eg, enoxaparin 40 mg daily, dalteparin 5000 U daily, or tinzaparin 4500 U daily in women of normal body weight) from early pregnancy (level of evidence: low).

Women with no personal history of venous thrombosis but who have a thrombophilic defect identified may require thromboprophylaxis. This will depend on the type of thrombophilia, the family history, and the presence of additional risk factors (eg, obesity, immobilization, and hyperemesis). All should be offered anticoagulant prophylaxis following delivery. The risk of thrombosis should be discussed with the patient antenatally and GEC stockings should be considered (level of evidence: low).

Women with antiphospholipid syndrome (lupus anticoagulant and/or antcardiolipin antibodies and/or Beta2-glycoprotein antibodies) and previous VTE or adverse pregnancy outcome should receive thromboprophylaxis with LMWH or LDUH and low-dose aspirin (75 mg/d)\textsuperscript{59,60} from the time of diagnosis of pregnancy (level of evidence: high). If there is a history of recurrent VTE an intermediate dose (75\% of treatment dose) or full treatment dose should be used.\textsuperscript{61} Aspirin is discontinued at 36 weeks of gestation to allow fetal platelets to recover. Prophylaxis with LMWH should continue for at least 7 days after delivery. In women with antiphospholipid syndrome and previous VTE, postpartum prophylaxis should be continued for 6 weeks (level of evidence: low).
**Table 5.3. Recommended Management Strategies for Various Clinical Situations (N.B. Specialist Advice for Individualized Management of Patients Is Advisable in Many of These Situations).**

| Clinical Situation                                                                 | Recommended Management                                                                 |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Single previous VTE (not pregnancy or "pill" related) associated with a transient risk factor and no additional current risk factors such as obesity. | Antenatal: surveillance or prophylactic doses of LMWH ± GEC stockings. Discuss decision regarding antenatal LMWH with the woman. Postpartum: anticoagulant therapy for at least 6 weeks ± GEC stockings. |
| Single previous idiopathic VTE or pregnancy or COC-related previous VTE or VTE with underlying thrombophilia and not on long-term anticoagulant therapy, or single previous VTE and additional current risk factors (eg, morbid obesity, nephrotic syndrome). | Antenatal: prophylactic doses of LMWH ± GEC stockings. Postpartum: anticoagulant therapy for at least 6 weeks ± GEC stockings. |
| More than 1 previous episode of VTE, with no thrombophilia and not on long-term anticoagulant therapy | Antenatal: prophylactic doses of LMWH ± GEC stockings. Postpartum: anticoagulant therapy for at least 6 weeks ± GEC stockings. |
| Previous episodes of VTE in women receiving long-term anticoagulants (eg, with underlying thrombophilia) | Antenatal: prophylactic doses of LMWH ± GEC stockings. Postpartum: resume long-term anticoagulants with LMWH overlap until INR in pregnancy therapeutic range ± GEC stockings. |
| Thrombophilia (confirmed laboratory abnormality) but no prior VTE. | Antenatal: surveillance or prophylactic LMWH ± GEC stockings. The indication for LMWH in the antenatal period is stronger in AT-deficient women than the other thrombophilias, in symptomatic kindred compared to asymptomatic kindred and also where additional risk factors are present. Postpartum: anticoagulant therapy for at least 6 weeks ± GEC stockings. |
| Following cesarean section | Carry out risk assessment for VTE. If additional risk factors such as emergency section in labor, age over 35 years, high BMI, and so on present, provide thromboprophylaxis at least until discharge from hospital. |
| Following vaginal delivery. | Carry out risk assessment for VTE. If 2 or more additional risk factors such as age over 35 years, high BMI, and so on present consider thromboprophylaxis ± GEC stockings at least until discharge from hospital. |

**Abbreviations:** AT, antithrombin; BMI, body mass index; COC, combined oral contraceptives; GEC, graduated elastic compression; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.

*NB where multiple risk factors are present consider extended prophylaxis after discharge.

**Table 5.4. Suggested Thromboprophylactic Doses for Antenatal and Postnatal LMWH.**

| Weight (kg) | Enoxaparin | Dalteparin | Tinzaparin (75 U/kg per day) |
|------------|------------|------------|-----------------------------|
| <50        | 20 mg daily| 2500 units daily | 3500 units daily |
| 50-90      | 40 mg daily| 5000 units daily | 4500 units daily |
| 91-130     | 60 mg dailyb| 7500 units dailyb | 7000 units dailyb |
| 131-170    | 80 mg dailyb| 10000 units dailyb | 9000 units dailyb |
| >170       | 0.6 mg/kg per dayb| 75 U/kg per dayb | 75 U/kg per dayb |
| High prophylactic (intermediate) dose for women 50-90kg | 40 mg 12-hourly | 5000 U 12-hourly | 4500 U 12-hourly |
| Treatment dose | 1 mg/kg per 12-hourly antenatal; 1.5 mg/kg daily postnatal | 100 U/kg per 12-hourly or 200 U/kg daily postnatal | 175 U/kg daily antenatal and postnatal |

**Abbreviation:** LMWH, low-molecular-weight heparin.

* RCOG Guideline 37a. May be given in 2 divided doses.

**Delivery and the Puerperium**

**Management of delivery.** Patients on LMWH antenatally and who wish epidural anesthesia should have heparin prophylaxis discontinued with the onset of labor. Epidural or spinal anesthesia is not advised for at least 12 hours after prophylactic LMWH administration and 24 hours after therapeutic doses have been discontinued. The LMWH should not be given for at least 4 hours after the epidural catheter has been inserted or removed and the catheter should not be removed within 10 to 12 hours of the most recent injection. For delivery by elective cesarean section, the woman should receive a thromboprophylactic dose of LMWH on the day before delivery. On the day of the delivery, the thromboprophylactic dose of LMWH should be given 4 hours after operation or 4 hours after removal of the epidural catheter (level of evidence: low). There is an increased risk of wound hematoma following cesarean section with both LMWH and LDUH. The subcutaneous injections should be given in the flank well away from the incision to minimize wound hematoma.
**Management of the puerperium.** In addition to previous VTE and thrombophilias, other risk factors should be considered for postpartum prophylaxis age above 35 years, obesity, cesarean section (particularly an emergency procedure during labor), gross varicose veins, preeclampsia, postpartum hemorrhage (>1000 mL) and immobilization (level of evidence: low).

Postpartum thromboprophylaxis is recommended in women with previous VTE, known thrombophilias, and other thrombotic risk factors. The first postpartum daily dose of subcutaneous LMWH (enoxaparin 40 mg, dalteparin 5000 U daily, or tinzaparin 75 U/kg) should be given 3 to 4 hours after delivery. Postpartum anticoagulation should be continued for a minimum of 6 weeks in high-risk patients with previous VTE or thrombophilia. In other patients not at high risk, prophylaxis should continue for 5 to 7 days, and the need for prophylaxis should be reviewed if the hospital stay continues beyond 7 days (level of evidence: moderate).

If a patient does not wish to continue on self-injections of LMWH, conversion to warfarin should be delayed until at least 5 to 7 days after delivery as warfarin will increase the risk of postpartum hemorrhage and perineal hematoma. The LMWH can be discontinued when the international normalized ratio has been within the target range of 2.0 to 3.0 for 2 consecutive days. The GEC stockings can be added to LMWH in high-risk patients and should be used where LMWH is contraindicated. Where anticoagulants are contraindicated, GEC stockings should be worn for at least 6 weeks following delivery (level of evidence: low).

Patients who develop VTE during pregnancy or the puerperium should be referred for hematological screening to determine whether they have underlying thrombophilia and counseled about the increased risk of hormone therapy. Progestogen-only contraception is suitable for these women. They should also be counseled about the need for prophylactic treatment in any future pregnancy.

Breast feeding is not contraindicated with either LMWH, LDUH, or warfarin (level of evidence: low).

**References**

1. Greer IA. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology. *Baillieres Clin Obstet Gynaecol.* 1997;11(3):403-430.
2. Report of the National Confidential Enquiry into perioperative Deaths. 1991/92. 1993.
3. Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a “high risk” group? *Am J Surg.* 1970;120(4):527-530.
4. Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. *Br Med J.* 1976;2(6041):910-912.
5. Havig O. Deep vein thrombosis and pulmonary embolism. An autopsy study with multiple regression analysis of possible risk factors. *Acta Chir Scand Suppl.* 1977;478:1-120.
6. Lowe GD, Carter DC, Prentice CR. Preoperative prediction of postoperative deep-vein thrombosis. *Lancet.* 1982;1(8287):1474.
7. Sue-Ling HM, Johnston D, McMahon MJ, Philips PR, Davies JA. Pre-operative identification of patients at high risk of deep venous thrombosis after elective major abdominal surgery. *Lancet.* 1986;1(8491):1173-1176.
8. Ageno W, Manfredi E, Dentali F, et al. The incidence of venous thromboembolism following gynecologic laparoscopy: a multicenter, prospective cohort study. *J Thromb Haemost.* 2007;5(3):503-506.
9. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. *Gynecol Oncol.* 2005;99(1):119-125.
10. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. *Thromb Haemost.* 2001;86(1):112-123.
11. Dawe F, Meltzer H. Contraception and Sexual Health 2002. A report on research using the ONS Omnibus Survey produced by the Office of National statistics on behalf of the Department of Health. London, 2003.
12. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis K. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. *Lancet.* 1995;346(8900):1589-1593.
13. Vessey MP, Doll R, Fairbairn AS, Glober G. Postoperative thromboembolism and the use of oral contraceptives. *Br Med J.* 1970;3(5715):123-126.
14. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. *Contraception.* 2004;70(6):437-441.
15. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. *Ann Intern Med.* 2000;132(9):689-696.
16. Greer IA, Walker ID. Hormone replacement therapy and venous thromboembolism. Royal College of Obstetricians and Gynaecologists, guideline no 19. London, 2004.
17. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet.* 2003;362(9382):428-432.
18. Nelson SM. Prophylaxis of VTE in women - during assisted reproductive techniques. *Thromb Res.* 2009;123(suppl 3):S8-S15.
19. Turner GM, Cole SE, Brooks JH. The efficacy of graduated compression stockings in the prevention of deep vein thrombosis after major gynaecological surgery. *Br J Obstet Gynaecol.* 1984;91(6):588-591.
20. Ballard RM, Bradley-Watson PJ, Johnstone FD, Kenney A, McCarthy TG. Low doses of subcutaneous heparin in the prevention of deep vein thrombosis after gynaecological surgery. *J Obstet Gynaecol Br Commonw.* 1973;80(5):469-472.
21. Taberner DA, Poller L, Burslem RW, Jones JB. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis. *Br Med J.* 1978;1(6108):272-274.
22. Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynaecological surgery. *Acta Obstet Gynecol Scand.* 1988;67(2):99-103.
23. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol. 2001;98(6):989-995.

24. Clarke-Pearson DL, Abaid LN. Prevention of venous thromboembolic events after gynecologic surgery. Obstet Gynecol. 2012;119(1):155-167.

25. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol. 1983;145(5):606-613.

26. Clark-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol. 1990;75(4):684-689.

27. ENOXACAN. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84(8):1099-1103.

28. Baykal C, Al A, Demirtas E, Ayhan A. Comparison of enoxaparin and standard heparin in gynecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001;22(22):127-130.

29. Fricker JP, Vergnes Y, Schach R, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest. 1988;18(6):561-567.

30. Heilmann L, Kruck M, Schindler AE. [Prevention of thrombosis in gynecology: double-blind comparison of low molecular weight heparin and unfractionated heparin]. Geburtshilfe Frauenheilkd. 1989;49(9):803-807.

31. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynecologic malignancy. Obstet Gynecol. 1984;63(1):92-98.

32. Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol. 1984;18(2):226-232.

33. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol. 1993;168(4):1146-1153.

34. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975-980.

35. Heit JA, Kobbervig CE, James AH, Pettersson TM, Bailey KR, Melton LJ, 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697-706.

36. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. Why mothers die 2000-2002. 6th report, RCOG Press, London; 2004.

37. Saving Mother’s Lives The 8th report on Confidential Enquiries into Maternal deaths in the UK. Br J Obstet Gynaecol. 2011;118:1-203.

38. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-1315.

39. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008;6(6):905-912.

40. De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 2006;135(3):386-391.

41. Pabinger I, Grafenhofer H, Kaider A, et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005;3(5):949-954.

42. Bonnar J. Venous thromboembolism and pregnancy. In: Dalen JE, ed. Venous Thromboembolism. New York, NY: Marcel Dekker; 2003:217-233.

43. Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2002;(2):CD001689.

44. Blanco-Molina A, Trujillo-Santos J, Criado J, Lopez L, et al. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry. Thromb Haemost. 2007;97(2):186-190.

45. Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol. 2005;131(1):80-90.

46. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(2):209-220.

47. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81(5):668-672.

48. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG. 2001;108(11):1134-1140.

49. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126 (suppl 3): 627S-644S.

50. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401-407.

51. Ensom MH, Stephenson MD. Low-molecular-weight heparins in pregnancy. Pharmacotherapy. 1999;19(9):1013-1025.

52. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997;176(5):1062-1068.

53. Pettika V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87(2):182-186.
Orthopedic Surgery and Trauma

General Considerations

Timing of Prophylaxis. Venous thromboembolism (VTE) prophylaxis involves a balance of risks and benefits. Chemical prophylaxis poses a dilemma, as the closer it is administered to surgery for a given dose, the better the thromboprophylaxis but the greater is the risk of bleeding complications. In Europe, low-molecular-weight heparin (LMWH) is given at a lower dose prior to operation providing an anticoagulant effect to counteract the intraoperative activation of coagulation factors and venous stasis. However, if a given dose of the drug is administered too long before surgery, then, intraoperative blood levels would be inadequate for effective prophylaxis, whereas if given too close to surgery then surgical bleeding is a threat. In North America, LMWH is given after surgery at a higher dose and more frequently. This should reduce the risk of surgical bleeding, yet intraoperative thrombogenesis is not prevented and thrombi may have already begun forming. The drug is now expected to be therapeutic as well as prophylactic. Therefore, prophylaxis needs to be given close but not too close to surgery.

Intermittent pneumatic compression (IPC) and foot impulse technology (FIT) sleeves are available in sterile packages that allow for intraoperative use, reducing both the risk of bleeding and the duration that the patient is not under LMWH prophylaxis.

Spinal and Epidural Anesthesia. Meta-analyses show that spinal and epidural anesthesia reduce both thromboembolism and perhaps mortality in hip fractures surgery and total knee replacement (TKR). This method does not reduce risk sufficiently on its own but should be regarded as a useful adjunct. Initial European experience suggested that neuraxial anesthesia could be safely used in the presence of LMWH. However, more recently there have been concerns that a spinal hematoma may develop on rare occasions. Guidelines have been suggested. The LMWH (or pentasaccharide) can be given safely 4 hours after removal of the epidural catheter (see section on Pregnancy). However, LMWH or pentasaccharide should be avoided while a continuous postoperative neuraxial block is in place. The catheter should not be inserted until serum levels of the chemical agent used are at their lowest. This means that postoperative administration of the agent is generally safer and more predictable than preoperative administration when epidural analgesia is needed.

Duration of Prophylaxis in Elective Orthopedic Surgery. Studies in patients having total hip replacement (THR) demonstrate that there is prolonged risk, with 45% to 80% of all symptomatic events occurring after discharge from the hospital. Randomized controlled trials (RCTs) in patients having THR indicate that prolonged thromboprophylaxis with LMWH for up to 35 days is safe and effective irrespective of whether in-hospital prophylaxis was with LMWH or warfarin. It decreases the frequency of venographically detected total deep vein thrombosis (DVT), proximal DVT, and symptomatic VTE after the seventh day by more than 50%. One RCT compared warfarin prophylaxis (international normalized ratio [INR] 2-3) for 9 days with warfarin extended for 1 month after hospital discharge. The VTE occurred in 5.1% of in-hospital prophylaxis patients and 0.5% in those having extended